4584 — Kidswell Bio Balance Sheet
0.000.00%
- ¥12bn
- ¥11bn
- ¥5bn
- 32
- 30
- 87
- 49
Annual balance sheet for Kidswell Bio, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 1,461 | 1,187 | 1,067 | 2,231 | 2,995 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 817 | 462 | 1,089 | 881 | 1,317 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3,346 | 3,326 | 3,697 | 4,924 | 6,701 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 3.22 | 1.64 | 1.48 | 1.32 | 1.19 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 3,934 | 3,503 | 3,895 | 5,086 | 7,008 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1,114 | 1,129 | 1,056 | 2,375 | 4,319 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 2,324 | 1,785 | 2,661 | 4,254 | 5,598 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 1,610 | 1,719 | 1,234 | 831 | 1,411 |
| Total Liabilities & Shareholders' Equity | 3,934 | 3,503 | 3,895 | 5,086 | 7,008 |
| Total Common Shares Outstanding |